Member Sign In

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

As per latest data published by the National Association of Home Builders (NAHB), housing starts across the U.S. rose 5.9% in the month of driven mainly by multi-family construction.

Housing starts for multi-family construction rose 26%, rebounding from a decline in the previous month. On the other hand, single-family construction declined 2.2%, narrowing from the positive growth seen in June.

Though an unusually wet weather in the South and West pulled down the single-family starts, rising interest rates, tight credit availability and a limited supply of land and labor also had a role to play.

With the recent improvement in economic conditions and the housing market in general, mortgage/interest rates are edging upwards to more normalized levels since May 2013. According to the Freddie Mac mortgage survey, the 30-year fixed mortgage rate has risen from 3.59% on May 23 to 4.40% as of Aug 15.

This has raised concerns among some analysts. High interest rates dilute the demand for new homes, as mortgage loans become expensive. This lowers a buyer’s purchasing power. However, another group of analysts believe that in spite of the recently rising interest rates they are still below historical levels and housing is still very much affordable.

Rising interest rates notwithstanding, some companies like Lennar Corporation (LEN - Free Report) -Free Report) and KB Home (KBH - Free Report) -Free Report) witnessed increasing demand in all their housing markets in the past quarter and were able to push pricing further. However, others showed some concern. D.R. Horton, Inc. (DHI - Free Report) -Free Report) noted at its fiscal third-quarter conference call that the spike in interest rates slowed orders Meritage Homes Corp. (MTH - Free Report) -Free Report), at its second-quarter 2013 conference call, admitted to a little bit of cooling in July due to higher rates, but reported that demand remained stronger than the Jul 2012 levels.

Moreover, supply of both new and existing homes remains constrained by low home inventories. A shortage of land and labor is restricting the construction of homes, both single and multi-family. Home prices have thus started to move up with market demand gaining momentum and supply remaining limited. In fact, a group of analysts believe that rising home prices and thinning home inventories have created a sense of urgency among homebuyers who are now more anxious to buy a house before prices shoot up further.

NAHB also reported that both the multi-family and single-family construction sectors are performing better than last year. Housing starts activity grew a solid 40.2% in the Northeast, 25.4% in the Midwest and 7.2% in the West in July, while it declined 7% in the South.

With the acquisition going through, Aragon’s lead pipeline candidate, ARN-509, has now become a part of Johnson & Johnson’s pipeline. ARN-509 is currently in phase II development for castration resistant prostate cancer (CRPC) and will be managed by Janssen Research & Development.

The $1 billion payout for the acquisition includes a $650 million upfront cash payment and up to $350 million on the achievement of milestones.

Prior to the closing of the acquisition, Aragon transferred all assets apart from the androgen receptor antagonist program to a newly formed company - Seragon Pharmaceuticals Inc., which was spun out of Aragon. Johnson & Johnson will neither have an ownership stake in Seragon nor will it retain any rights to the products or programs transferred to the company.

Our Take

This acquisition signifies Johnson & Johnson’s attempt to strengthen its prostate cancer franchise especially once Zytiga loses exclusivity. Zytiga, which became a part of Johnson & Johnson’s portfolio following its acquisition of Cougar Biotechnology, is one of the company’s most successful launches in recent times. Zytiga sales in the recently reported second quarter of 2013 were $395 million, up 70.3% year over year. The successful development of ARN-509 will consolidate the company’s position in the prostate cancer market.

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Resources

Client Support

Follow Us

Zacks Research is Reported On:

Yahoo

MSN

Marketwatch

Nasdaq

Forbes

Investors.com

Morningstar

Zacks Investment Research is an A+ Rated BBB Accredited Business.

Copyright 2016 Zacks Investment Research

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1988-2015 and were examined and attested by Baker Tilly Virchow Krause, LLP, an independent accounting firm.

Visit performance for information about the performance numbers displayed above.